Nawroth P P, Ziegler R
Abteilung Innere Medizin I, Medizinische Universitätsklinik, Heidelberg.
Klin Wochenschr. 1991 May 24;69(8):335-9. doi: 10.1007/BF02115778.
Oral contraceptives are being associated with an increased risk of thrombosis. Measurements of clotting factor abnormalities in plasma can not predict the individual risk of thrombosis, nor can they explain the pathophysiology of the clinically known association of thrombosis and oral contraceptives. Research conducted over the last 10 years points to the important role of endothelial cells, fibroblasts and monocytes in the regulation of the initiation of coagulation. Hence we propose, that the molecular mechanism of oral contraceptive associated thrombosis can only be elucidated by studies looking at the effect of these drugs on cellular elements involved in coagulation. Measurements of plasmatic coagulation factors can not indicate safety or risk for a patient taking any of the multiple drugs available.
口服避孕药与血栓形成风险增加有关。血浆中凝血因子异常的检测既无法预测个体的血栓形成风险,也无法解释临床上已知的血栓形成与口服避孕药之间关联的病理生理学机制。过去10年进行的研究表明,内皮细胞、成纤维细胞和单核细胞在凝血起始调节中起重要作用。因此,我们提出,只有通过研究这些药物对参与凝血的细胞成分的影响,才能阐明口服避孕药相关血栓形成的分子机制。血浆凝血因子的检测无法表明服用多种现有药物中任何一种的患者的安全性或风险。